期刊
ONCOIMMUNOLOGY
卷 2, 期 2, 页码 -出版社
TAYLOR & FRANCIS INC
DOI: 10.4161/onci.22730
关键词
targeted therapy; immunotherapy; dasatinib; anti-OX40; C-KIT mutant tumors
In a mastocytoma model expressing mutant c-KIT, a combination of the c-KIT inhibitor dasatinib and an OX40-specific monoclonal antibody synergized in triggering a strong antitumor T-cell response that promoted curative therapeutic effects. Along with a number of other recent studies, these data support the notion that combining targeted agents with immunotherapy may constitute a promising approach for cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据